AMCP Foundation P&T Competition 2025 Velsipity Drug Overview

Event Type:
Webinars
Date:
Monday, January 6, 2025 | 7-8pm ET

The study drug for the 2025 P&T Competition is VELSIPITY™ (etrasimod). Velsipity is a sphingosine 1-phosphate receptor modulator indicated for the treatment of moderately to severely active ulcerative colitis (UC) in adults. This webinar provides an overview of the competition drug for participants.

The deadline for entries to the 2025 National P&T Competition (one entry per pharmacy school) is 11:59 pm EST on Monday, January 20, 2025.

Link to Webinar Coming Soon.

Member:
Free
Non-Member:
Free